Comparative Effectiveness and Safety of LAMA-LABA Inhalers in Chronic Obstructive Pulmonary Disease

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Health Services Research

Background:

• Long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) dual bronchodilator therapy is recommended for symptomatic chronic obstructive pulmonary disease (COPD).
• Fixed-dose LAMA-LABA inhalers are available in various device types, including dry powder, metered-dose, and soft mist inhalers.
• Concerns exist regarding greenhouse gas emissions from metered-dose inhalers and potential differences in effectiveness among LAMA-LABA therapies due to variations in active ingredients, dosing, and devices.

Purpose of the Study:

• To compare the effectiveness and safety of once-daily umeclidinium-vilanterol dry powder inhalers, twice-daily glycopyrrolate-formoterol metered-dose inhalers, and once-daily tiotropium-olodaterol soft mist inhalers.
• To evaluate time to first moderate or severe COPD exacerbation, major adverse cardiovascular events, urinary tract infections, and pneumonia hospitalizations.

Main Methods:

• An observational, active-comparator study analyzing claims data from patients (≥40 years) newly treated with LAMA-LABA inhalers.
• Propensity score matching was used to create 1:1 cohorts for comparison.
• The study included patients continuously enrolled in a health insurance or Medicare Advantage plan, with data analyzed from May 2016 to February 2025.

Main Results:

• Umeclidinium-vilanterol was associated with a 14% lower hazard of COPD exacerbation compared to glycopyrrolate-formoterol (HR, 0.86; NNT, 17).
• Compared to tiotropium-olodaterol, umeclidinium-vilanterol showed a 3% lower hazard of COPD exacerbation (HR, 0.97; NNT, 100).
• Tiotropium-olodaterol demonstrated a 6% lower hazard of COPD exacerbation than glycopyrrolate-formoterol (HR, 0.94). Similar risks for cardiovascular events, UTIs, and pneumonia were observed across all cohorts.

Conclusions:

• Once-daily umeclidinium-vilanterol dry powder inhalers demonstrated improved clinical outcomes, specifically reduced COPD exacerbations, compared to glycopyrrolate-formoterol and tiotropium-olodaterol.
• The findings suggest that umeclidinium-vilanterol may be a preferred option for new users of LAMA-LABA therapy.
• Patients, prescribers, and health systems can consider these comparative effectiveness data when selecting LAMA-LABA inhalers.